from the quickly evolving industry of oncology investigate, accurate and efficient mutation screening is critical for developing qualified therapies. The KRAS products and services Platform plays a pivotal role Within this landscape by featuring extensive alternatives for KRAS mutation profiling and analysis. KRAS mutations, present in close to nin